Handa Pharmaceuticals, Inc. (TPEX:6620)

Handa Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,497	1,807	597.38	667.05	365.91	263.31
Short-Term Investments	2,230	1,896	1,232	1,650	-	19.96
Cash & Short-Term Investments	3,727	3,704	1,829	2,317	365.91	283.27
Cash Growth	30.89%	102.45%	-21.04%	533.18%	29.18%	-10.10%
Accounts Receivable	365.95	580.02	190.44	376.37	153.48	7.79
Other Receivables	35.74	6.49	29.29	6.74	8.02	7.62
Receivables	401.69	586.51	219.73	383.11	161.51	15.4
Inventory	-	-	41.24	-	-	-
Prepaid Expenses	18.52	17.36	12.16	11.63	2.42	2.33
Other Current Assets	23.43	4.79	2.66	3.27	63.02	13.34
Total Current Assets	4,171	4,312	2,105	2,715	592.86	314.33
Property, Plant & Equipment	108.19	84.86	75.78	21.03	43.04	41.83
Long-Term Investments	59.61	59.93	62.2	61.86	-	-
Goodwill	35.9	35.89	35.93	34.95	34.95	34.95
Other Intangible Assets	664.91	730.49	917.05	0.59	1.07	1.31
Long-Term Deferred Tax Assets	285.63	266.28	243.52	202.85	117.23	105.18
Other Long-Term Assets	255.79	402.8	1.72	1.04	1.43	0.93
Total Assets	5,581	5,893	3,441	3,037	790.56	498.53

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	45.53	30.23	20.78	13.97	6.22	1.08
Accrued Expenses	29.7	53.51	33.29	51.38	18.53	14.61
Current Portion of Leases	10.42	10.22	7.27	5.57	10.14	6.2
Current Income Taxes Payable	26.71	14.43	-	124.76	1.34	0.01
Other Current Liabilities	352.37	9.45	180.02	13.81	9.13	7.84
Total Current Liabilities	464.74	117.84	241.36	209.49	45.35	29.73
Long-Term Leases	30.6	37.41	32.83	7.67	19.46	5.7
Long-Term Unearned Revenue	27.45	27.71	42.62	-	-	-
Long-Term Deferred Tax Liabilities	9.72	10.1	7.28	23.81	4.63	-
Other Long-Term Liabilities	25.39	39	-	39.92	-	-
Total Liabilities	557.91	232.05	324.09	280.88	69.44	35.43

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,700	1,700	1,412	1,411	1,302	1,221
Additional Paid-In Capital	3,094	3,094	1,254	1,253	579.02	338.41
Retained Earnings	828.78	1,058	546.87	215.2	-1,089	-1,049
Treasury Stock	-560.78	-114.4	-56.52	-	-	-
Comprehensive Income & Other	-39.07	-77.26	-39.45	-123.18	-70.76	-47.93
Shareholders' Equity	5,023	5,660	3,117	2,756	721.12	463.1
Total Liabilities & Equity	5,581	5,893	3,441	3,037	790.56	498.53

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	41.03	47.64	40.1	13.24	29.59	11.89
Net Cash (Debt)	3,686	3,656	1,789	2,304	336.32	271.38
Net Cash Growth	31.79%	104.32%	-22.33%	584.95%	23.93%	-10.06%
Net Cash Per Share	22.69	23.54	12.68	17.10	2.68	2.31
Filing Date Shares Outstanding	162.53	168.53	140.48	141.09	130.16	122.13
Total Common Shares Outstanding	162.53	168.53	140.48	141.09	130.16	122.13
Working Capital	3,706	4,194	1,864	2,505	547.5	284.61
Book Value Per Share	30.90	33.59	22.19	19.54	5.54	3.79
Tangible Book Value	4,322	4,894	2,164	2,721	685.11	426.85
Tangible Book Value Per Share	26.59	29.04	15.41	19.28	5.26	3.50
Machinery	83.84	51.86	60.95	55.98	66.98	76.07
Leasehold Improvements	15.32	15.32	15.3	12.64	15.54	15.49

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 7, 2026

Data Sources Report a data error